25193-95-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinemethanol is used as a reagent for the synthesis of melanin-concentrating hormone receptor 1 (MCHR1) antagonists. These antagonists have potential applications in the treatment of various disorders, such as obesity and anxiety, by modulating the activity of MCHR1 receptors in the body.
Used in Organic Chemistry:
5-Pyrimidinemethanol is also used in the preparation of annulated 5-aryl-substituted pyridines, which are important intermediates in the synthesis of various pharmaceutical compounds and organic molecules. The annulation process involves the formation of a ring structure by connecting two or more atoms, which can enhance the stability and reactivity of the resulting compounds.

InChI:InChI=1/C5H6N2O/c8-3-5-1-6-4-7-2-5/h1-2,4,8H,3H2

Upstream product

• 40929-50-8 ethyl pyrimidine-5-carboxylate 
• 10070-92-5 pyrimidine-5-carbaldehyde 

Downstream Products

• 144164-23-8 carbonic acid 4-nitro-phenyl ester pyrimidin-5-ylmethyl ester 
• 1141080-80-9 pyrimidin-5-ylmethyl 4-methylbenzenesulfonate 
• 1450723-44-0 N-[(4-morpholinosulfonylphenyl)methyl]-1,3-dihydropyrrolo[3,4-c]pyridine-2-carboxamide 
• 147740-04-3 ethyl 1H,2H,3H-pyrrolo[3,4-c]pyridine-2-carboxylate 
• 496-13-9 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine 
• 1454251-17-2 1,3-dihydropyrrolo[3,4-c]pyridin-2-carboxylic acid [5-(3-trifluoromethylbenzenesulfonyl)pyridin-2-ylmethyl]amide 
• 126230-78-2 5-(2-Propynyloxymethyl)pyrimidine 
• 25198-96-3 5-(bromomethyl)pyrimidine 
• 25198-95-2 (pyrimidin‐5‐yl)methanamine 
• 1383916-51-5 N-[(5-pyrimidinyl)methyl]-2-pyridinamine 
• 10070-92-5 pyrimidine-5-carbaldehyde 

Relevant academic research and scientific papers

Investigation of liver alcohol dehydrogenase catalysis using an NADH biomimetic and comparison with a synthetic zinc model complex

We have compared the catalytic activity of horse liver alcohol dehydrogenase (LADH) with a synthetic zinc model complex in the presence of N-benzyl-1,4-dihydronicotinamide (BNAH), a cofactor which serves as a biomimetic for the natural cofactor NADH. We have used five different substrates (benzaldehyde, p-anisaldehyde, 4-nitrobenzaldehyde, 2-pyridine carboxaldehyde, and 5-pyrimidine carboxaldehyde) in this study. These substrates vary in their substituent inductive effect, which is the ability to donate or withdraw electron density away from their carbonyl-functional group. Our results reveal that in the presence of NADH, geometric factors (induced fit of the substrate and cofactor in the enzyme active site) are vital. However, reactivity assays show that in the presence of BNAH, there is a strong correlation between substrate electronic environment and the observed catalytic rate, i.e. the more electron withdrawn the substrate, the greater the speed at which the reduction reaction occurs. NMR spectroscopy reveals that a synthetic zinc model complex catalyzes the reduction of substrates in a manner consistent with LADH enzyme.

Controlled meta-Selective C-H Mono- And Di-Olefination of Mandelic Acid Derivatives

Mandelic acids represent a key structural motif present in many drug molecules. Herein, we report the controlled meta-selective mono- and diolefination of mandelic acids by the careful design of the substrate and oxidant. Furthermore, free meta-functional

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,